Bortezomib reduces pre-existing antibodies to recombinant immunotoxins in mice.


Recombinant immunotoxin (RIT) therapy is limited in patients by neutralizing Ab responses. Ninety percent of patients with normal immune systems make neutralizing Abs after one cycle of RIT, preventing repeated dosing. Furthermore, some patients have pre-existing Abs from environmental exposure to Pseudomonas exotoxin, the component of the RIT that elicits… (More)
DOI: 10.4049/jimmunol.1402324


5 Figures and Tables